ArticleInvestigative ophthalmology & visual science2026
Olink Proteomic Profiling of Vitreous Humor and Plasma From Proliferative Diabetic Retinopathy Patients Identifies a Novel Inflammatory Molecular Endotype.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize proteomic profiles and underlying biological processes in vitreous humor and plasma of patients with proliferative diabetic retinopathy (PDR), diabetic patients without retinopathy (Non_DR), and non-diabetes mellitus patients (Non_DM), and to identify the molecular endotypes within PDR patients. Methods: Proteomic profiling of paired vitreous humor and plasma samples from 47 PDR patients, 26 Non_DR patients, and 48 Non_DM patients were conducted with Olink platform. The Olink platform includes 13 panels targeting 1161 proteins. Gene set enrichment analysis was applied for enriched pathways, and the K-means clustering method was used to identify different PDR clusters based on vitreous proteomic profiles. Results: Proteomic analysis revealed significant differences in the vitreous humor of PDR patients compared to those in the Non_DR or Non_DM groups, with elevation of carbonic anhydrase (CA) family members as potential contributors to PDR pathophysiology. Plasma samples from PDR group exhibited less profound differences in proteomic profiles compared to the other two groups. Clustering analysis of PDR vitreous samples identified three distinct clusters as molecular endotypes of PDR patients. Of those, Cluster 3 was characterized by enrichment in CCL/CXCL/IL6/IL18 chemokines and pro-inflammatory signaling pathways, which may contribute to more severe PDR phenotypes. Conclusions: Significant differences in proteomic profiles were observed in PDR patients, especially in vitreous samples, with CA family members identified as potential therapeutic targets for PDR. Endotyping analysis of vitreous samples uncovered unique patient population with enriched CCL/CXCL/IL6/IL18 inflammatory pathways, highlighting the significance of local protein signature changes in PDR disease heterogeneity and its potential applications in patient stratification and therapeutic treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.